You can now read 10 articles each month for free on

The Boston Globe


Vertex Pharma.

Continue reading below

Cambridge biotech company Vertex Pharmaceuticals Inc. paid its departing chief executive, Matthew W. Emmens, $13.3 million last year, down from $14.9 million in 2010, according to a regulatory filing. His compensation included a $1.1 million salary, an incentive plan payment of $3 million, and stock and option grants totaling $9.1 million. He stepped down Feb. 1. Jeffrey Leiden took over the job.

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week